Context Therapeutics has been added to the Russell 2000 and Russell 3000 indices effective June 26, 2026. The Russell 3000 index comprises the 3000 largest publicly traded companies in the U.S., representing about 98% of the investable market, while the Russell 2000 is a subset that serves as a leading benchmark for U.S. small-cap equities. Context is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies targeting solid tumors, including CTIM-76, CT-95, and CT-202. Shares closed Monday at $0.64, down 2.46%, and were trading at $0.66 in the pre-market, up 3.43%.
Context Therapeutics IncInclusion in Russell indices typically triggers passive fund buying and increased visibility.